A comprehensive, multi-center US study involving 67 eligible patients examined the effectiveness of fecal microbiota, live-jslm (RBL), as a treatment option for recurrent Clostridioides difficile infection (rCDI). Results indicate a treatment success rate of 77.6% at an 8 week mark. Furthermore, a robust 87% of participants sustained remission at six months, reinforcing the safety and…
A recent phase 3b clinical trial has revealed promising results in the fight against recurrent Clostridioides difficile infection (rCDI). Specifically, the study showed that Rebyota Fecal Microbiota, live-jslm (RBL), administered through colonoscopy, is a safe and efficacious preventative measure for those susceptible to recurrent bouts of the infection. The trial serves as a benchmark for…
In a recent comparative study reported in Open Forum Infectious Diseases, the role of infectious disease specialists (IDS) in the management of Clostridioides difficile infection (CDI) revealed significant clinical benefits. The study, conducted across two Spanish hospitals with contrasting IDS availability during the period of January to December 2021, demonstrated the potential of IDS-centric intervention…
Transforming Clostridioides difficile Infection Management: An Insight into Fecal Microbiota Therapy
In a bid to combat the resurgence of potentially debilitating Clostridioides difficile infection (CDI), healthcare professionals have pivoted towards new therapeutics. Clostridioides difficile, a bacterium that colonizes the gut, incites a disruption in the gut microbiome leading to dysbiosis, thereby paving the way for infections. Posing a higher risk to the elderly (over 65), the…